Uncategorized

GSK, Hansoh ADC extends survival in lung cancer study

Published

on

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version